Cancer therapy using natural ligands that target estrogen receptor beta.
10.1016/S1875-5364(15)30083-2
- Author:
Gangadhara R SAREDDY
1
;
Ratna K VADLAMUDI
2
,
3
Author Information
1. Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
2. Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
3. Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: Vadlamudi@uthscsa.edu.
- Publication Type:Journal Article
- Keywords:
ER beta agonists;
Estrogen receptor;
Estrogen receptor beta;
Genistein;
Liquiritigenin;
S-equol;
Tumor suppressor
- MeSH:
Antineoplastic Agents, Phytogenic;
pharmacology;
therapeutic use;
Equol;
pharmacology;
therapeutic use;
Estrogen Receptor beta;
antagonists & inhibitors;
metabolism;
Flavanones;
pharmacology;
therapeutic use;
Genistein;
pharmacology;
therapeutic use;
Glycyrrhiza;
chemistry;
Humans;
Ligands;
Neoplasms;
drug therapy;
metabolism;
Phytotherapy;
Plant Extracts;
pharmacology;
therapeutic use;
Soybeans;
chemistry
- From:
Chinese Journal of Natural Medicines (English Ed.)
2015;13(11):801-807
- CountryChina
- Language:English
-
Abstract:
Estrogen receptor beta (ERβ) is one of the two key receptors (ERα, ERβ) that facilitate biological actions of 17β-estradiol (E2). ERβ is widely expressed in many tissues, and its expression is reduced or lost during progression of many tumors. ERβ facilitates estrogen signaling by both genomic (classical and non-classical) and extra-nuclear signaling. Emerging evidence suggests that ERβ functions as a tissue-specific tumor suppressor with anti-proliferative actions. Recent studies have identified a number of naturally available selective ERβ agonists. Targeting ERβ using its naturally available ligands is an attractive approach for treating and preventing cancers. This review presents the beneficial actions of ERβ signaling and clinical utility of several natural ERβ ligands as potential cancer therapy.
